(PFE/ENTA)—Nice catch—I missed that detail. As noted in the WSJ article in #msg-162737917, the oral protease inhibitor mentioned in PFE’s PR today, PF-07321332, is simply a reformulation of PF-07304814, the SARS protease inhibitor PFE discovered in 2003 that PFE has been testing against COVID in a phase-1b trial that started in Sep 2020.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.